Catalyst Pharmaceuticals Stock Investor Sentiment
CPRX Stock | USD 22.89 1.23 5.68% |
Slightly above 67 percent of all Catalyst Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that a large number of traders are confidant. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 67
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Catalyst Historical Sentiment
Although Catalyst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Catalyst, such as negative comments on social media and news outlets, may cause fear in the market and push Catalyst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Catalyst.
Catalyst |
Catalyst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Catalyst Pharmaceuticals Historical Investor Sentiment
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts
Catalyst Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Catalyst Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Catalyst Pharmaceuticals' options.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
Timeline |
1 | Acquisition by Miller Steve of 235000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 12/13/2024 |
2 | Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 12/16/2024 |
3 | Acquisition by Harper Molly of 1333 shares of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
4 | Disposition of 8667 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/31/2024 |
5 | Disposition of 10600 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/02/2025 |
6 | Heres Why Catalyst Pharmaceutical is a Strong Momentum Stock - Yahoo Finance | 01/24/2025 |
7 | Moody Aldrich Partners LLC Sells 60,990 Shares of Catalyst Pharmaceuticals, Inc. - MarketBeat | 01/29/2025 |
8 | Financial Backing Strengthens Catalyst Pharmaceuticals Presence | 01/31/2025 |
9 | Catalyst Pharmaceuticals Rating Increased to Strong-Buy at Baird R W | 02/05/2025 |
10 | Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 | 02/12/2025 |
11 | Insider Trading | 02/13/2025 |
12 | Disposition of 2353 shares by Elsbernd Brian of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
13 | Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.s Performance Completely | 02/21/2025 |
14 | Disposition of 4000 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/24/2025 |
15 | Catalyst Pharmaceuticals Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 02/25/2025 |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.